Chloride Losing
Diarrhoea
Dr Prakash. I
Introduction
 Rare
 Difficult to diagnose and manage
 AR inheritance
 1945-Holmberg, Wedejoja et al- watery diarrhoea + high chloride
content of stool + metabolic alkalosis: “metabolic alkalosis with
diarrhoea” or “congenital chloridorrhea”
 Finland 1960s- Finland- “CLD/ CCD”
 genetic origin
 Treatment
Incidence
• Kuwait- 1/3200 Single cases may appear world wide
• Saudi Arabia -1/5000 Mutation analysis –in low incidence countries
• Finland-1/30,000-40,000
• Poland -1/200,000
Pathophysiology
 Function of chloride
 Regulate cell volume
 Fluid secretion
 Acid base balance
 Defect: SLC26A3 (solute carrier
protein), loss of SLC26A3
mediated transport
 Diarrhoea
 Secretory (large volume,
NPO no effect)
 Osmotic (low volume)
Pathophysiology cont…..
 SLC26A3 gene (family of 26 member, >30 mutations) encodes for
a trans-membrane protein {apical epithelial (Cl⁄HCO3)
exchanger}
 Result:
 defective Gut absorption of Cl and secretion of HCO3
 The coupled epithelial Na+⁄H+ transport through the
Na+⁄H+ exchangers (NHE2 and⁄ or NHE3) is defective
& leads to
 intestinal loss of both NaCl, fluid
 watery Cl rich diarrhoea.
At birth
 Distended abdomen
 Visible peristalsis
 Most are LBW
 d/d: intestinal obstruction
 D1: Profuse watery diarrhea
?????urine, misdiagnosed as
delayed passage of meconium
CCD Vs GI obstruction
 Family history (AR)
 Local demographics
 Normal peristalsis
 ANSS:
 Generalized dilatation of gut
with polyhydramnious
 Increase chloride in AF
Diagnosis
 Typical clinical picture:
 Watery diarrhea since birth
 Metabolic alkalosis
 High fecal chloride >90 mmol/L
 fecal pH between 4 and 6
 Genetic testing for mutation
 If excessive fluid loss and salt depletion*:
 ↓diarrhea & low faecal Cl of even 40 mmol/L
 Repeat faecal samples for diagnosis
 >3 months of life:
 diagnosis by high fecal chloride concentration
In the 1st hour after birth
Dehydration, Hypochloremia, Hyponatremia,
Activate renin-angiotensin system
Hyperaldosteronism (compensatory mechanism) →K+ depletion and metabolic
alkalosis
Laboratory findings (untreated): hypochloraemia, hypokalemia and metabolic
alkalosis
Immuno-histochemical staining of the congenital chloride
diarrhea protein. A) Normal colon (left). B.) CCLD (right).
Complications
 Diarrhoea and fecal incontinence-
 Life long
 No of stools: 2-7L/day
 Renal injury-
 Major complication
 Chronic hypovolemia →secondary effects
 ↑ renin, aldosterone with secondary hyperaldosteronism
 Vascular changes –hypertensive changes (±BP)
 Chronic K+ loss→ impaired function of renal tubular and
intestinal absorptive cells
Complications……..
 Male subfertility –
 low concentration of poorly motile spermatozoa
 abnormal morphology +
 high seminal chloride with low pH
 large bilateral spermatoceles
 Hyperuricaemia & gout –
 age dependent increasing risk
 Sweat gland-
 increased chloride (similar to CF)
Management
 Neonatal period: NaCl and KCl added to IV
maintenance fluids
120-300 mL/day (patients aged 0-7 days)
500-700 mL/day (patients aged more than
7days)
Bicarbonate free fluid
 IV → PO: Q8/Q6 H
Salt substitution therapy (NaCl and KCl)
Salt replacement therapy
 ↑ intestinal absorption (mechanisms-not known)
 Inhibits development of hypochloraemic and hypokalaemic metabolic
alkalosis
 Despite t/t:
 Diarrhoea is persistent (defective SLC26A3-mediated anion transport
remains in the intestine)
 ↑ age: ↓ in amount of stools & electrolytes, but continuous loss of Cl
 Insufficient replacement: Cl-free urine*
 Adequate salt replacement: excretion of Cl in urine, ± electrolyte and
acid base status
The rationale:
Proton pump inhibitor (Omeprazole)
 Inhibition of gastric chloride secretion
protect endogenous chloride stores
reduce the amount of chloride presented to the
intestine
 ↓ in volume and frequency of stools
 Cessation of incontinence
Oral Butyrate
 Short-chain FA
 Easily administered
 Prevent severe dehydration episodes
 Stimulates intestinal water and ion absorption (activation of a
parallel Cl-/butyrate and Na+/H+ exchanger, inhibit both basal
and adenosine 3’,5’-cyclic monophosphate–stimulated Cl
secretion)
 Trophic effects : mediated through circulatory, hormonal, and
neural mechanisms
Cholestyramine
 Binds bile acids → reduces intestinal secretion
 Moderate reduction in diarrhoea (for 2 to 4
weeks)
Outcome
 From fatal → treatable disease
 Prompt recognition and management of
electrolyte loss
↓Constant dehydration
↓Dys/Hypoelectrolytemia
↑growth and development
↓Renal involvement
↓Activation of renin aldosterone system
Chloride losing diarrhoea prakash

Chloride losing diarrhoea prakash

  • 1.
  • 2.
    Introduction  Rare  Difficultto diagnose and manage  AR inheritance  1945-Holmberg, Wedejoja et al- watery diarrhoea + high chloride content of stool + metabolic alkalosis: “metabolic alkalosis with diarrhoea” or “congenital chloridorrhea”  Finland 1960s- Finland- “CLD/ CCD”  genetic origin  Treatment
  • 3.
    Incidence • Kuwait- 1/3200Single cases may appear world wide • Saudi Arabia -1/5000 Mutation analysis –in low incidence countries • Finland-1/30,000-40,000 • Poland -1/200,000
  • 4.
    Pathophysiology  Function ofchloride  Regulate cell volume  Fluid secretion  Acid base balance  Defect: SLC26A3 (solute carrier protein), loss of SLC26A3 mediated transport  Diarrhoea  Secretory (large volume, NPO no effect)  Osmotic (low volume)
  • 5.
    Pathophysiology cont…..  SLC26A3gene (family of 26 member, >30 mutations) encodes for a trans-membrane protein {apical epithelial (Cl⁄HCO3) exchanger}  Result:  defective Gut absorption of Cl and secretion of HCO3  The coupled epithelial Na+⁄H+ transport through the Na+⁄H+ exchangers (NHE2 and⁄ or NHE3) is defective & leads to  intestinal loss of both NaCl, fluid  watery Cl rich diarrhoea.
  • 6.
    At birth  Distendedabdomen  Visible peristalsis  Most are LBW  d/d: intestinal obstruction  D1: Profuse watery diarrhea ?????urine, misdiagnosed as delayed passage of meconium
  • 7.
    CCD Vs GIobstruction  Family history (AR)  Local demographics  Normal peristalsis  ANSS:  Generalized dilatation of gut with polyhydramnious  Increase chloride in AF
  • 8.
    Diagnosis  Typical clinicalpicture:  Watery diarrhea since birth  Metabolic alkalosis  High fecal chloride >90 mmol/L  fecal pH between 4 and 6  Genetic testing for mutation  If excessive fluid loss and salt depletion*:  ↓diarrhea & low faecal Cl of even 40 mmol/L  Repeat faecal samples for diagnosis  >3 months of life:  diagnosis by high fecal chloride concentration
  • 9.
    In the 1sthour after birth Dehydration, Hypochloremia, Hyponatremia, Activate renin-angiotensin system Hyperaldosteronism (compensatory mechanism) →K+ depletion and metabolic alkalosis Laboratory findings (untreated): hypochloraemia, hypokalemia and metabolic alkalosis
  • 10.
    Immuno-histochemical staining ofthe congenital chloride diarrhea protein. A) Normal colon (left). B.) CCLD (right).
  • 11.
    Complications  Diarrhoea andfecal incontinence-  Life long  No of stools: 2-7L/day  Renal injury-  Major complication  Chronic hypovolemia →secondary effects  ↑ renin, aldosterone with secondary hyperaldosteronism  Vascular changes –hypertensive changes (±BP)  Chronic K+ loss→ impaired function of renal tubular and intestinal absorptive cells
  • 12.
    Complications……..  Male subfertility–  low concentration of poorly motile spermatozoa  abnormal morphology +  high seminal chloride with low pH  large bilateral spermatoceles  Hyperuricaemia & gout –  age dependent increasing risk  Sweat gland-  increased chloride (similar to CF)
  • 13.
    Management  Neonatal period:NaCl and KCl added to IV maintenance fluids 120-300 mL/day (patients aged 0-7 days) 500-700 mL/day (patients aged more than 7days) Bicarbonate free fluid  IV → PO: Q8/Q6 H Salt substitution therapy (NaCl and KCl)
  • 14.
    Salt replacement therapy ↑ intestinal absorption (mechanisms-not known)  Inhibits development of hypochloraemic and hypokalaemic metabolic alkalosis  Despite t/t:  Diarrhoea is persistent (defective SLC26A3-mediated anion transport remains in the intestine)  ↑ age: ↓ in amount of stools & electrolytes, but continuous loss of Cl  Insufficient replacement: Cl-free urine*  Adequate salt replacement: excretion of Cl in urine, ± electrolyte and acid base status The rationale:
  • 16.
    Proton pump inhibitor(Omeprazole)  Inhibition of gastric chloride secretion protect endogenous chloride stores reduce the amount of chloride presented to the intestine  ↓ in volume and frequency of stools  Cessation of incontinence
  • 17.
    Oral Butyrate  Short-chainFA  Easily administered  Prevent severe dehydration episodes  Stimulates intestinal water and ion absorption (activation of a parallel Cl-/butyrate and Na+/H+ exchanger, inhibit both basal and adenosine 3’,5’-cyclic monophosphate–stimulated Cl secretion)  Trophic effects : mediated through circulatory, hormonal, and neural mechanisms
  • 18.
    Cholestyramine  Binds bileacids → reduces intestinal secretion  Moderate reduction in diarrhoea (for 2 to 4 weeks)
  • 19.
    Outcome  From fatal→ treatable disease  Prompt recognition and management of electrolyte loss ↓Constant dehydration ↓Dys/Hypoelectrolytemia ↑growth and development ↓Renal involvement ↓Activation of renin aldosterone system